At 35 and rather near the end of his career, Souleymane Bamba has other priorities in mind. His Cardiff City club (Championship) announced very bad news on Monday evening. The central defender suffers from cancer of the lymphatic system. He has even already started chemotherapy. “Sol started his fight in a positive frame of mind and will continue to be an integral part of the Bluebirds family” indicates the statement of the Welsh club.
Arrived at the Bluebirds in 2016, Bamba, who is now a substitute, had a great history with Cardiff since he was part of the team that rose to the Premier League in 2018. Trained at PSG, he also had the selection of Côte d’Ivoire cumulating 46 selections with the Elephants, participating in the 2014 World Cup and becoming vice-champion of Africa in 2012. “Sol will continue to support his teammates in matches and at the Academy with our youth teams, with whom he will continue his training as a coach” informs the Cardiff press release.
We are saddened to inform supporters that Sol Bamba has been diagnosed with Non-Hodgkin lymphoma.
With the close support of the Club’s medical team, Sol has immediately started a course of chemotherapy treatment.
We are all with you, Sol. 💙 pic.twitter.com/O2KSn4nAoh
— Cardiff City FC (@CardiffCityFC) January 11, 2021
*The article has been translated based on the content of Foot Mercato : Info Transferts Football – Actu Foot Transfert by www.footmercato.net. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.
*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!